UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000025524
Receipt number R000029363
Scientific Title A multi-institutional study analyzing effect of a novel lozenge containing polaprezinc for patients treated with high dose chemotherapy followed by hematopoietic stem cell transplantation
Date of disclosure of the study information 2017/01/04
Last modified on 2020/05/19 17:44:04

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A multi-institutional study analyzing effect of a novel lozenge containing polaprezinc for patients treated with high dose chemotherapy followed by hematopoietic stem cell transplantation

Acronym

A multi-institutional study analyzing effect of polaprezinc lozenge

Scientific Title

A multi-institutional study analyzing effect of a novel lozenge containing polaprezinc for patients treated with high dose chemotherapy followed by hematopoietic stem cell transplantation

Scientific Title:Acronym

A multi-institutional study analyzing effect of polaprezinc lozenge

Region

Japan


Condition

Condition

Hematological malignancy

Classification by specialty

Hematology and clinical oncology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

Severe oral mucositis often occures in patients receiving the conditioning high-dose chemotherapy for hematopoietic stem cell transplant, and is associated with discontinuation of therapy. In the present study, we evaluate clinical effect of the lozenge preparation in patients receiving high dose chemotherapy for hematopoietic stem cell transplantation.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Phase II,III


Assessment

Primary outcomes

Incidence of grade>2 oral mucositis during 35 days after start of chemotherapy

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Medicine

Interventions/Control_1

Prevention group
Intervention periods:35 days

Interventions/Control_2

Treatment group

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit

90 years-old >

Gender

Male and Female

Key inclusion criteria

1 Patients with hematopoietic malignancy receiving high dose chemotherapy followed by hematopoietic stem cell transplantation
2 Patients with ECOG performance ststus under 2
3 Patients aged over 18 years and under 90

Key exclusion criteria

1 Patients aged under 18 years
2 Patients with oral mucositis at the start of chemotherapy

Target sample size

100


Research contact person

Name of lead principal investigator

1st name Hisashi
Middle name
Last name Tsurumi

Organization

Gifu University Graduate School of Medicine

Division name

First Department of Internal Medicine

Zip code

5011194

Address

1-1 Yanagido, Gifu City

TEL

058-230-7530

Email

htsuru@gifu-u.ac.jp


Public contact

Name of contact person

1st name Akio
Middle name
Last name Suzuki

Organization

Gifu University Hospital

Division name

Department of Pharmacy

Zip code

5011194

Address

1-1 Yanagido, Gifu City

TEL

058-230-7091

Homepage URL


Email

akio@gifu-u.ac.jp


Sponsor or person

Institute

Gifu University

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

The ethics committee of the Gifu University Graduate School of Medicine

Address

1-1 Yanagido, Gifu

Tel

058-230-6059

Email

rinri@gifu-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2017 Year 01 Month 04 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

91

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2016 Year 12 Month 07 Day

Date of IRB

2018 Year 12 Month 06 Day

Anticipated trial start date

2017 Year 01 Month 04 Day

Last follow-up date

2019 Year 03 Month 31 Day

Date of closure to data entry

2019 Year 08 Month 27 Day

Date trial data considered complete

2019 Year 08 Month 27 Day

Date analysis concluded

2020 Year 01 Month 31 Day


Other

Other related information



Management information

Registered date

2017 Year 01 Month 04 Day

Last modified on

2020 Year 05 Month 19 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000029363


Research Plan
Registered date File name
2018/10/03 研究計画書(UMIN000025524).doc

Research case data specifications
Registered date File name

Research case data
Registered date File name